Dr. Donna A. Shriner received her Bachelor’s degree in pharmacy from West Virginia University in 1983 and began work as a hospital pharmacist in a small community hospital in southern West Virginia. In 1985-86, she completed an American Society of Hospital Pharmacy (ASHP) – accredited residency in clinical pharmacy at the National Institutes of Health before entering the Doctor of Pharmacy program at the University of Texas in 1986. After graduation from UT, she returned to the east coast and completed a specialized residency in pediatrics with a focus in pediatric hematology / oncology at the Children’s Hospital of Philadelphia and the Philadelphia College of Pharmacy and Science. In 1989, she moved to Gainesville, Florida and began a three year post-doctoral fellowship in oncology / bone marrow transplantation at the University of Florida.
In 1992, she was recruited by the Radiation Epidemiology Branch (REB) of NCI’s Division of Cancer Epidemiology and Genetics (DCEG) to assist with a planned study of second cancers after bone marrow transplantation. Before joining REB full time in May 1993, she completed her Masters in Public Health at The Johns Hopkins University. For the next 3½ years, Dr. Shriner worked with the Fred Hutchinson Cancer Research Center and the International Bone Marrow Transplant Registry on the initial REB – sponsored studies of second cancers after bone marrow transplantation.
In November 1995, Dr. Shriner joined the Pharmaceutical Management Branch of the Cancer Therapy Evaluation Program to consolidate and manage the expanding portfolio of blinded clinical trials. Since joining PMB, Dr. Shriner has been involved in the development and management of more then 50 blinded protocols. In addition to her expertise in the pharmaceutical aspects of blinded study design, Dr. Shriner is also responsible for several of CTEP’s core databases including the CTEP Investigator Registration (IR) database, the CTEP Identity and Access Management (IAM) application, and the Enterprise Core Module (ECM).